TY - JOUR
T1 - Role of HER-2/neu overexpression and clinical features at presentation as predictive factors in meningiomas
AU - Potti, Anil
AU - Panwalkar, Amit
AU - Langness, Eric
AU - Sholes, Kaley
AU - Tendulkar, Ketki
AU - Chittajalu, Siddarth
AU - Koch, Michael
PY - 2004/10
Y1 - 2004/10
N2 - Prediction of outcome in patients with meningiomas remains a significant problem to date. We have evaluated the role of symptoms at presentation and overexpression of her-2/neu overexpression as independent prognostic factors in meningiomas. In a retrospective study on patients with biopsy-proven diagnosis of meningioma, her-2/neu overexpression was evaluated using immunohistochemistry (IHC) performed on paraffin-embedded specimens. An IHC score of ≥2+ was considered positive for overexpression. Two hundred thirty-seven patients thus identified between January 1986 and December 1999 included 149 females and 88 males, with a mean age of 63.44 years. Survival was estimated using the Kaplan-Meier method. Incidence of meningiomas in females (62.8%) was significantly greater than in males. Focal neurodeficits, headache, and seizures (39.66%) were the most common presenting complaints and were not related to tumor behavior/outcome. Syncope at presentation was associated with a decreased survival, but this symptom constituted only 2.53% of the total, so reliable conclusions could not be drawn. Only 6 (2.53%) specimens revealed HER-2/neu overexpression by IHC. HER-2/neu overexpression is not a predictor of tumor behavior and has no role as a prognostic factor in meningiomas. Syncope as the clinical presentation at diagnosis may predict a poor outcome, but needs further investigation.
AB - Prediction of outcome in patients with meningiomas remains a significant problem to date. We have evaluated the role of symptoms at presentation and overexpression of her-2/neu overexpression as independent prognostic factors in meningiomas. In a retrospective study on patients with biopsy-proven diagnosis of meningioma, her-2/neu overexpression was evaluated using immunohistochemistry (IHC) performed on paraffin-embedded specimens. An IHC score of ≥2+ was considered positive for overexpression. Two hundred thirty-seven patients thus identified between January 1986 and December 1999 included 149 females and 88 males, with a mean age of 63.44 years. Survival was estimated using the Kaplan-Meier method. Incidence of meningiomas in females (62.8%) was significantly greater than in males. Focal neurodeficits, headache, and seizures (39.66%) were the most common presenting complaints and were not related to tumor behavior/outcome. Syncope at presentation was associated with a decreased survival, but this symptom constituted only 2.53% of the total, so reliable conclusions could not be drawn. Only 6 (2.53%) specimens revealed HER-2/neu overexpression by IHC. HER-2/neu overexpression is not a predictor of tumor behavior and has no role as a prognostic factor in meningiomas. Syncope as the clinical presentation at diagnosis may predict a poor outcome, but needs further investigation.
KW - Her-2/neu overexpression
KW - Meningioma
KW - Predictive factors
KW - Symptoms
UR - http://www.scopus.com/inward/record.url?scp=5644291956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=5644291956&partnerID=8YFLogxK
U2 - 10.1097/01.coc.0000128724.63600.c7
DO - 10.1097/01.coc.0000128724.63600.c7
M3 - Article
C2 - 15596909
AN - SCOPUS:5644291956
SN - 0277-3732
VL - 27
SP - 452
EP - 456
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
IS - 5
ER -